Skip to main content

Table 4 Other secondary adverse events in patients treated with ACP or RIVP + ACP during TARS

From: Retrograde inferior vena caval perfusion for total aortic arch replacement surgery: a randomized pilot study

Outcome

ACP group

(n = 38)

RIVP + ACP group

(n = 38)

P value

Surgical re-exploration for bleeding

2 (5.3)

0 (0)

Deep sternal wound infectiona

1 (2.6)

1 (2.6)

1.00

Length of intubation, hourb

47 (19, 89)

25 (13, 66)

0.022

Length of hospital stay, daysb

16 (12, 20)

13 (10, 18)

0.36

Red blood cells, unitsb

6.5 (2.0, 13.0)

3.8 (1.5, 6.5)

0.047

Fresh frozen plasma, unitsb

2.0 (0, 4.7)

0.8 (0, 3.0)

0.26

Platelet, unitsb

2.0 (2.0, 3.0)

2.0 (2.0, 2.0)

0.023

  1. Continuous data are expressed as median (interquartile range); categorical data, as n (%)
  2. ACP antegrade cerebral perfusion, RIVP retrograde inferior vena caval perfusion, TARS total aortic replacement surgery
  3. aChi-squared test
  4. bMann–Whitney U test